Expression and clinical significance of long non-coding RNA exocyst complex component 7 in hepatocellular carcinoma

Fang ZhangYing; Zhu ChuanWei; Zhang QingSong; He YongYong

doi:10.3969/j.issn.1001-5256.2019.01.023

Volume 35 Issue 1

Jan. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(1): 123-126

PDF( 2034 KB)

Expression and clinical significance of long non-coding RNA exocyst complex component 7 in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.01.023

Department of Clinical Laboratory, Xuancheng Central Hospital, Xuancheng, Anhui 242000, China

Published Date: 2019-01-20

Abstract

Abstract

Objective To investigate the expression and clinical significance of long non-coding RNA (lncRNA) exocyst complex component 7 (EXOC7) in hepatocellular carcinoma (HCC) .MethodsA total of 79 pairs of HCC tissue samples and adjacent tissue samples were collected from the patients who underwent HCC surgery from January 2010 to January 2014.Real-time PCR was used to measure the expression of lncRNA EXOC7 in HCC tissue and adjacent tissue, and its association with pathological features and prognosis was analyzed.The t-test was used for comparison of continuous data between two groups, and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups.The Kaplan-Meier method was used for the analysis of survival and recurrence curves after surgery, and the Cox regression model was used for the analysis of survival and recurrence data.ResultsThe expression of lncRNA EXOC7 in HCC tissue was significantly higher than that in adjacent tissue (6.211±0.637 vs 2.924±0.415, t=4.106, P<0.01) .The expression of lncRNA EXOC7 was associated with tumor size (χ2=5.157, P=0.023) , presence or absence of portal vein tumor thrombus (χ2=4.049, P=0.044) , presence or absence of organ metastasis (χ2=4.345, P=0.037) , and TNM stage (χ2=6.479, P=0.011) .The high lncRNA EXOC7 expression group had significantly shorter disease-free survival and overall survival than the low lncRNA EXOC7expression group (χ2=8.215, P<0.001;χ2=6.091, P=0.001) .The Cox multivariate regression analysis showed that lncRNA EXOC7expression, tumor size, portal vein tumor thrombus, organ metastasis, and TNM stage were independent factors for the prognosis of HCC (all P<0.05) .Conclusion LncRNA EXOC7 is involved in the regulation of the development and progression of HCC and may become a new reference index for the prognosis of HCC.
- liver neoplasms,
- LncRNA EXOC7,
- prognosis

FullText(HTML)

References(21)

References

[1]CHERT W, ZHENG R, BAADE PD, et al.Cancer statistics in china, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]TORE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[3]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.

[4]QI X, ZHAO Y, LI H, et al.Management of hepatocellular carcinoma:An overview of major findings from meta-analyses[J].Oncotarget, 2016, 7 (23) :34703-34711.

[5]OLIVERI RS, WETTERSLEV J, GLAND C.Hepatocellular carcinoma[J].Lancet, 2012, 380 (9840) :470-481.

[6]GUO W, DONG Z, SHI Y, et al.Methylation-mediated down regulation of long noncoding RNA LOC 100130476 in gastric cardia adenocarcinoma[J].Clin Exp Metastasis, 2016, 33 (5) :497-508.

[7]JIA J, LI F, TANG XS, et al.Long non-coding RNA DANCRpromotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3[J].Oncotarget, 2016, 7 (25) :37868-37881.

[8]ANGEL DL, SONIA G, MANEL E, et al.Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer[J].Proc Natl Acad Sci USA, 2016, 113 (47) :e7535-e7544.

[9]ADAM M, HWARD Y.Long noncoding RNAs in cancer pathways[J].Cancer Cell, 2016, 29 (4) :452-463.

[10]GEISLER S, COLLER J.RNA in unexpected places:long noncoding RNA functions in diverse cellular contexts[J].Nat Rev Mol Cell Biol, 2013, 14 (11) :699-712.

[11]MERCER TR, OINGER ME, MATTICK JS, et al.Long noncoding RNAs:Insights into functions[J].Nat Rev Genet, 2009, 10 (3) :155-159.

[12]JIA M, JIANG L, WANG YD, et al.LncRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through notch signaling-induced epithelial-mesenchymal transition[J].Hepatol Res, 2016, 46 (11) :1137-1144.

[13]SHULLA S, ZHANG X, NIKNAFS YS, et al.Identification and validation of PCAT14 as prognostic biomarker in prostate cancer[J].Neoplasia, 2016, 18 (8) :489-499.

[14]LUKA B, MRTKA R, DAMJAN G.Long Noncoding RNAs as Biomarkers in Cancer[J].Dis Markers, 2017, 5 (10) :1155-1169.

[15]LI H, MA SQ, ZHOU HH, et al.Roles of long non-coding RNAs in colorectal cancer metastasis[J].Oncotarget, 2017, 8 (24) :39859-39876.

[16]YANG YL, QIAN JX, QU JM, et al.The prognostic value of long non-coding RNA HOTTIP on clinical outcomes in breast cancer[J].Oncotarget, 2017, 8 (4) :6833-6844.

[17]HUANG MD, CHEN WM, SHU YQ, et al.Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2[J].Molecular Cancer, 2015, 14 (10) :1186-1198.

[18]HUA L, WANG CY, MA WL, et al.High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma[J].Int J Clin Exp Pathol, 2015, 8 (3) :3076-3082.

[19]ZENG L, YANG RX, BAI YF, et al.The relationship between the expression of LncRNA EXOC7 and the prognosis patients with small cell lung cancer[J].Tumor, 2017, 37 (3) :269-274. (in Chinese) 曾丽, 杨濡溪, 白义凤, 等.小细胞肺癌组织中LncRNA EXOC7的表达及其与预后的关系[J].肿瘤, 2017, 37 (3) :269-274.

[20]RINN JL, KERTESA M, WANG JK, et al.Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs[J].Cell, 2007, 129 (7) :1311-1323.

[21]YU W, GIUS D, ONYANGO P, et al.Epigenetic silencing of tumor suppressor gene p15 by its antisense RNA[J].Nature, 2008, 451 (7175) :202-206.

Relative Articles

[1]	Zhiying LIU, Zhihang ZHOU, Song HE. Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(10): 2470-2475. doi: 10.3969/j.issn.1001-5256.2023.10.028
[2]	Baiyu JI, Fenlin HAO, Jiangtao HAI, Junsheng ZHANG, Xiangyang WU, Dong JIN, Zhenhui LU. A prognostic analysis of transcatheter arterial chemoembolization combined with local ablation in treatment of recurrent liver cancer after surgery[J]. Journal of Clinical Hepatology, 2022, 38(7): 1572-1576. doi: 10.3969/j.issn.1001-5256.2022.07.021
[3]	Xuchu LIU, Shiyun QIN, Lijun CHEN, Juan CHEN, Xiaoguang YOU. Prognostic value of KRAS mutations in patients with advanced primary liver cancer treated with transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2022, 38(11): 2514-2519. doi: 10.3969/j.issn.1001-5256.2022.11.015
[4]	Weimeng HE, Zhiming ZHANG, Jinlin HOU, Yajing HE. Effect of entecavir antiviral therapy on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2021, 37(3): 601-605. doi: 10.3969/j.issn.1001-5256.2021.03.019
[5]	Jian LI, Yaqiu DU, Dezhao LI, Huifan JI, Chenggang ZHANG, Qingxia LIU, Xiaolin GUO. Current status of research on the prognostic markers for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(11): 2701-2705. doi: 10.3969/j.issn.1001-5256.2021.11.047
[6]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[7]	Tao BAI, Jingli WANG, Xudong HU, Bing XIA, Hailin CHENG, Juan WANG. Association of the expression level of the long non-coding RNA TINCR in peripheral blood with Th1/Th2 balance and prognosis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(1): 79-83. doi: 10.3969/j.issn.1001-5256.2021.01.016
[8]	Luo Qiong, Wang ChunMing, Liao HangYu, Chen KunLing, Pan MingXin. Value of the NDRG family in the diagnosis and prognostic evaluation of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1284-1288. doi: 10.3969/j.issn.1001-5256.2020.06.019
[9]	Tan ZhengRong, Feng DaLi, Zhang Qing. Expression of intergenic long non-coding RNA RP11-488L18.10 in cholangiocarcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1087-1090. doi: 10.3969/j.issn.1001-5256.2020.05.027
[10]	Zhong LanHai, Ma DanDan, Zhang ZhiYong, Zhang Yi, Cai Xun. Expression of FAM134B in liver cancer and its association with prognosis: An analysis based on data mining[J]. Journal of Clinical Hepatology, 2019, 35(11): 2508-2512. doi: 10.3969/j.issn.1001-5256.2019.11.023
[11]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[12]	Liu YeYing, Wang Ting, Dou AiHua, Zheng SuJun, Xu Bin, Liu Mei. Current status and perspectives of prognostic markers for liver failure[J]. Journal of Clinical Hepatology, 2019, 35(5): 1135-1139. doi: 10.3969/j.issn.1001-5256.2019.05.046
[13]	Li TianTian, Sun Jing, Wang Quan, Ding JunQiang, Wang Jia, Xue Hui, Zhang Tao, Duan XueZhang. Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1702-1706. doi: 10.3969/j.issn.1001-5256.2018.08.022
[14]	Li ZhiBin, Xiao DongSheng, Song Wei. Prognostic value of preoperative platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1734-1739. doi: 10.3969/j.issn.1001-5256.2017.09.021
[15]	Li MengGe, Zhao YaLin, Liu XiaoLi, Wang XinHui, Jiang YuYong, Yang ZhiYun. Effect of different minimally invasive therapies on the prognosis of patients with HBV-related primary liver cancer complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2017, 33(4): 684-688. doi: 10.3969/j.issn.1001-5256.2017.04.017
[16]	Wang XiaoFang, Zhu LiYing, Lu BaoLing, Zhong LiHua, Cheng Yu, Fan Jian, Yao Hong, Yu Lei. Application of different scoring systems in evaluating prognosis after transarterial chemoembolization for primary liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(10): 2016-2020. doi: 10.3969/j.issn.1001-5256.2017.10.036
[17]	Huang Yu, Huang Di, Liu Shuo, Weng JieFeng, Zhang Shuai, Zhang Qiang, Mai ZhenHao, Gu WeiLi. Clinical features of non- B non- C hepatocellular carcinoma and virus-associated hepatocellular carcinoma and re-lated prognostic factors[J]. Journal of Clinical Hepatology, 2016, 32(3): 514-517. doi: 10.3969/j.issn.1001-5256.2016.03.024
[18]	Fang ZiYan, Jin Shuai, Li Gong. Efficacy and prognostic factors of intensity-modulated radiotherapy for large primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 886-890. doi: 10.3969/j.issn.1001-5256.2015.06.014
[19]	Zhang YuLing, Han Tao, Zhang Min, Zhang Qian. Research progress in prognostic markers of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1078-1081. doi: 10.3969/j.issn.1001-5256.2014.10.026
[20]	Liu XiaoYan, Li ShengMian, Yang Jian. The incidence and prognosis of non-alcoholic fatty liver disease in primary liver cancer 1293 cases[J]. Journal of Clinical Hepatology, 2010, 26(6): 641-643.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	朱惠刚，刘东升，贾楷桥. 腹腔镜下精准肝切除术与常规腹腔镜肝肿瘤切除术治疗原发性肝癌的效果及安全性. 中西医结合肝病杂志. 2022(07): 648-650 .
2.	邓明，邓芳，陈志坚，周福生. 连翘苷对胃癌细胞AGS增殖、迁移和侵袭的抑制作用. 中成药. 2022(09): 3009-3012 .
3.	赵金磊，季春勇，石伟，罗红杰，季予江，刘东亮. 长链非编码RNA MIAT在肝细胞癌组织中的表达及临床意义. 临床肿瘤学杂志. 2021(03): 217-221 .
4.	侯亚萍，张小晶，李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系. 肝脏. 2021(07): 757-760 .
5.	陈绪林，姜宇，赵艳，李彩华，高逸之. 原发性肝癌组织中miR-557的表达及其与预后的关系. 国际消化病杂志. 2021(04): 313-316 .
6.	杜小梅，吕建宁，李雯. 长链非编码RNA EXOC7在非小细胞肺癌中的表达及临床意义分析. 临床肺科杂志. 2020(04): 592-595 .
7.	林洁，黄炳臣，王娟，黄云美，黄小英. 肝癌患者组织及血清微小RNA-24和微小RNA-629的表达水平及其临床意义. 广西医学. 2020(14): 1775-1778 .
8.	梅洪亮，黄致远，胡逸林，江艳，陈敏，卢绮萍，刘志苏. 长链非编码RNA KCNQ1重叠转录物1在肝细胞癌迁移及增殖和侵袭中的作用与机制研究. 中华消化外科杂志. 2020(10): 1083-1090 .
9.	杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响. 中国临床药理学与治疗学. 2019(06): 630-636 .
10.	钟蓝海，马丹丹，张智勇，张翌，蔡逊. 基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系. 临床肝胆病杂志. 2019(11): 2508-2512 . 本站查看
11.	唐丽，唐华，孙强. FOXM1、FOXO3a在肝癌中的表达及其临床意义. 临床医学研究与实践. 2019(36): 24-26 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1665) PDF downloads(305)

Expression and clinical significance of long non-coding RNA exocyst complex component 7 in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.01.023